This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN with mild proteinuria in children.
Henoch-Schonlein purpura nephritis (HSPN) is one of the most common complications of Henoch-Schonlein purpura, and has become one of the main causes of chronic kidney disease in children. However, the diagnosis and treatment of HSPN is still based on the clinical experience, lacking of evidence-based support. This study is performed to explore the biological markers for early prediction of the prognosis and evaluate the efficacy and safety of various measures in the treatment of HSPN in children. The patients who are proved to get HSPN by renal biopsy will be randomized to receive either prednisone p.o. or angiotensin-converting enzyme inhibitor(ACEI) p.o. We will follow up them for about 2.5 years and compare the efficacy and safety of both measures by monitoring several indexes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
1.5mg/kg/d
0.2-0.3mg/kg/d
Nanjing Children's Hospital
Nanjing, Jiangsu, China
RECRUITINGDisappearance of proteinuria
The proteinuria is \< 150mg/d
Time frame: 30 months
Disappearance of hematuria
The number of red blood cells is \< 3 in each high power field of vision
Time frame: 30 months
Renal function
The glomerular filtration rate is normal
Time frame: 30 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.